Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Multiple Myeloma 76Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Burkitt Lymphoma 17Recurrence 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia, Biphenotypic, Acute 6Neoplasms, Plasma Cell 5Lymphoma 5Immunoglobulin Light-chain Amyloidosis 5Smoldering Multiple Myeloma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Leukemia 4Neoplasm Metastasis 3Down Syndrome 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Prostatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia, Hairy Cell 2Hodgkin Disease 2Fatigue 2Brain Neoplasms 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2

Interventions

Cyclophosphamide 47Rituximab 31fludarabine 29Specimen Handling 13Magnetic Resonance Spectroscopy 13Doxorubicin 13pirtobrutinib 11Vincristine 11Prednisone 11fludarabine phosphate 10Immunotherapy, Adoptive 10Etoposide 10Bendamustine Hydrochloride 10obinutuzumab 8Lenalidomide 8Biopsy 8venetoclax 7polatuzumab vedotin 7glofitamab 7zanubrutinib 6pembrolizumab 6Dexamethasone 6tafasitamab 5ibrutinib 5etoposide phosphate 5acalabrutinib 5Leukapheresis 5tazemetostat 4loncastuximab tesirine 4Nivolumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × Calcium Dobesilate × 1 year × Clear all
NCT06230224 2026-05-11

OLYMPIA-4

Regeneron Pharmaceuticals

Phase 3 Active not recruiting
216 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT05016947 2026-01-29

Venetoclax Plus Inotuzumab for B-ALL

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
23 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡